Kristen Fortney
Showing 1–2 of 2 transcripts.
- Milken Institute59 min
Longevity Lab: Can You Live to 100? | Global Conference 2024
Allison Aubrey, James Bethell, Dan Buettner, Peter Diamandis, Kristen Fortney, Lloyd Minor
A panel of scientists and policymakers discusses converging strategies to achieve longevity escape velocity through the integration of AI-driven biotech, emerging drugs like rapamycin and GLP-1 agonists, and preventative Blue Zone principles that emphasize environmental design over individual willpower. With the XPRIZE Healthspan Competition challenging teams to reverse functional aging within a decade and healthcare systems pivoting from sick care to community-based prevention, the dialogue highlights a transition toward treating aging as a manageable biological process rather than an inevitable decline. While optimistic projections suggest widespread adoption of anti-aging therapies within twenty years, experts caution that true success requires balancing pharmacological interventions with social determinants of health to ensure extended healthspan alongside increased lifespan.
- a16z18 min
a16z Podcast | How to Live Longer and Better
Kristen Fortney, Jeff Kaditz, David Sinclair, Michael Snyder, Hanne Tidnam, Hannah, Mike Snyder
Driven by an explosion of biological data and computing power, the longevity sector is transitioning from reactive treatment to proactive precision health, with experts projecting a potential 5 to 15-year increase in human healthspan. Key advancements in tracking molecular signatures and removing senescent cells aim to compress morbidity and save the U.S. healthcare system approximately $3 to $4 trillion by reducing chronic disease prevalence. Despite ongoing debates over data ownership and clinical trial limitations, the convergence of continuous monitoring and pharmacological interventions is establishing a new framework for extending functional life.